Описание
Duloxetine and sumatriptan co-administration carries a serotonin syndrome risk due to complementary mechanisms of serotonergic stimulation.
Механизм
Duloxetine inhibits both SERT and NET; sumatriptan activates 5-HT1B/1D receptors, producing overlapping serotonergic stimulation.
Клиническое значение
FDA labeling for triptans warns of serotonin syndrome risk when combined with serotonergic drugs including SNRIs.
Тактика ведения
Use with caution; counsel patients on warning signs of serotonin syndrome and seek immediate medical care if symptoms develop.
Медицинский отказ от ответственности
This content is for educational and informational purposes only. It is not a substitute for professional medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider before making medication decisions.